February 7 , 2019
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

# Notice Concerning Non-operating Expenses

SymBio Pharmaceuticals Limited ("the Company") announces the accrued non-operating expenses for the fourth quarter of the fiscal year ended December 31, 2018 (from October 1, 2018 to December 31, 2018) as follows.

1. Details of Non-operating Expenses

   The Company recorded a foreign exchange loss of 55,570 thousand yen under non-operating expenses for the fourth quarter of the fiscal year ended December 31, 2018 (from October 1, 2018 to December 31, 2018) due to the recent changes in foreign exchange rates. In addition, with a foreign exchange gain of 1,466 thousand yen for the third quarter ended September 30, 2018, a total foreign exchange loss of 54,103 thousand yen was recorded as statements of operations for the fiscal year ended December 31, 2018.

2. Future Outlook

   Regarding the impact of the above non-operating loss on the results of Company operations, please refer to the "Summary of Financial Statements for the Fiscal Year Ended December 31, 2018 [Japanese GAAP] (Non-consolidated)" announced today.

**[Contact]**
Investor Relations
Tel: +81(0)3 5472 1125